Genelux (GNLX) FCF Margin (2022 - 2024)

Genelux's (GNLX) quarterly FCF Margin came in at 54800.0% in Q1 2024, down 5203588.0% year-on-year from N/an in Q2 2023, and down 1882.55% quarter-over-quarter from 2764.12% in Q1 2023.

Genelux (GNLX) FCF Margin (2022 - 2024) Analysis & Trends

Genelux's FCF Margin history runs 3 years deep, the most recent figure standing at 54800.0% for Q1 2024.

  • On a quarterly basis, FCF Margin fell 5203588.0% year-over-year to 54800.0% in Q1 2024; TTM through Dec 2024 was 270112.5%, a 25758309.0% decrease from a year earlier, with the FY2025 full-year figure at 329575.0%, down 5946250.0% from the prior year.
  • FCF Margin slipped to 54800.0% in Q1 2024 per GNLX's latest filing, from 2764.12% in the prior quarter.
  • Across five years, FCF Margin topped out at 14.02% in Q4 2022 and bottomed at 54800.0% in Q1 2024.
  • The 3-year median for FCF Margin is 2764.12% (2023), against an average of 19183.37%.
  • Biggest YoY gain for FCF Margin was 5203588 bps in 2024; the steepest drop was 5203588 bps in 2024.
  • Year by year, FCF Margin stood at 14.02% in 2022, then plunged by 19820 bps to 2764.12% in 2023, then slumped by 1883 bps to 54800.0% in 2024.
  • Per Business Quant, the three latest GNLX FCF Margin figures stand at 54800.0% (Q1 2024), 2764.12% (Q1 2023), and 14.02% (Q4 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.45%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 43.35%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 23.53%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Genelux 129.36 Mn 129.36 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2024 -54,800.00%
Mar 31, 2023 -2,764.12%
Dec 31, 2022 14.02%